Summary: The fiscal year 2025 (FY25) Peer Reviewed Cancer Research Program (PRCRP) Clinical Development Award - Fellow and Resident Option (CDA-FRO) supports the advancement of cancer research through development of early-career investigators. Under this award mechanism, the early-career investigator is considered the Principal Investigator (PI), and the application should focus on the PI’s research and career development. The proposed research should address a critical problem in at least one of the FY25 PRCRP topic areas and at least one of the FY25 PRCRP strategic goals and should be designed to advance cancer research and/or improve patient care.

Distinctive Features: There are two distinct early-career development options: the Fellow Option and the Resident Option. For the Fellow Option the PI must be an early-career researcher or physician-scientist (referred to as a Fellow) within seven years after completion of their terminal degree by the time of the application deadline (excluding time spent in residency, clinical training or on family medical leave). For the Resident Option the PI must be an early-career clinician performing their residency with an interest in becoming a physician-scientist.

Career Guide: Inclusion of a Career Guide, experienced cancer researcher, as demonstrated by a strong record of funding and publications, is required for both the Fellow Option and the Resident Option. The Career Guide must demonstrate a commitment to advancing the PI’s career in cancer research.

Funding Details: (New for FY25) Funding limits are now listed as total cost limits, which is the combination of both direct and indirect costs.

Miscellaneous

• Unrestricted